Background-Nitrates may be beneficial in heart failure with preserved ejection fraction (HFpEF) by enhancing cGMP signaling and improving hemodynamics, but real-world data on potential efficacy are lacking. Methods and Results-We linked the Swedish Heart Failure Registry to national registries with International Classification of Diseases, Tenth Revision comorbidity diagnoses and demographic and socioeconomic data. In HFpEF, defined as left ventricular ejection fraction ≥40%, we derived propensity scores for nitrate use using 52 baseline variables. The association between nitrate use and all-cause mortality and the composite of all-cause mortality or first heart failure hospitalization was assessed in a cohort matched 2:1 untreated to treated based on age and propensity score. Matching yielded 2235 treated versus 4470 untreated patients, with 1-year survival of 80% (95% CI, 78%-82%) versus 79% (95% CI, 78%-81%) and hazard ratio of 1.06 (95% CI, 0.98-1.15; P=0.12). Nitrates were associated with worse composite outcome in the matched HFpEF cohort, with 1-year event-free survival of 62% (95% CI, 60%-64%) versus 65% (95% CI, 63%-66%) and hazard ratio of 1.11 (95% CI, 1.04-1.18; P=0.003). These patterns were reproduced in several consistency analyses. Conclusions-In HFpEF, the use of nitrates was not associated with improvements in all-cause mortality or heart failure hospitalization. (Circ Heart Fail. 2017;10:e003534.
H eart failure with preserved ejection fraction (HFpEF) is the dominant form of heart failure (HF) in aging societies 1 ; yet, we lack proven therapies to improve outcomes. Downregulation of the NO-soluble guanylyl cyclase (sGC)-cGMP pathway has been suggested to play a key role in the pathophysiology of HFpEF. Drugs targeting the NO-sGC-cGMP pathway are in various phases of trial and development. Exogenous NO donors have been postulated to enhance NO-sGC-cGMP signaling with resultant beneficial hemodynamic and myocardial effects in HFpEF. 2 However, chronic nitrate use may paradoxically worsen endothelial function. 3, 4 Furthermore, HFpEF patients are more prone to symptomatic hypotension as a result of nitrate therapy, given their sensitivity to changes in left ventricular (LV) preload and afterload. 5, 6 See Clinical Perspective
The NEAT-HFpEF trial (Nitrate's effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction) showed adverse effects of nitrates on activity levels, if any. 7 Neutral findings were also observed in the multicenter RELAX trial (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction), in which increasing cGMP concentration through the inhibition of its metabolism by phosphodiesterase-5 failed to improve exercise capacity in HFpEF. 8 However, selective randomized controlled trials may not be generalizable to broader populations.
Thus, the potential for nitrates and other drugs targeting the NO-sGC-cGMP pathway in HFpEF remains unclear. Using real-world data from the nationwide Swedish Heart Failure Registry, we tested the hypothesis that use of nitrates is associated with improved outcomes in a broad unselected HFpEF population.
Methods

Study Design
The Swedish Heart Failure Registry (SwedeHF) has been previously described 9, 10 and provided the study population and baseline clinical characteristics and medications. The inclusion criterion is clinician-judged HF, regardless of LV ejection fraction (LVEF). Approximately 80 variables are recorded at discharge from hospital or outpatient visits at cardiology, internal medicine, geriatrics, and primary care clinics and entered into a database managed by Uppsala Clinical Research Center (www.ucr.se). The protocol, case report form, and annual reports are available at www. SwedeHF.se.
All Swedish citizens have unique 10-digit personal identification numbers that enable record linking of disease-specific health registries and national health and census registries. Additional baseline comorbidity data were obtained from the National Patient Registry from The Swedish Board of Health and Welfare (www.socialstyrelsen.se). It contains International Classification of Diseases, Tenth Revision (ICD-10) codes (Table I in the Data Supplement) for encounters as inpatients and outpatients at specialty clinics. The positive predictive value for most ICD-10 diagnoses in Sweden is 85% to 95%.
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Comorbidities present at baseline were defined by corresponding ICD-10 codes in any position between January 1, 1997, when use of ICD-10 codes began in Sweden, and up to and including the index date (except malignancy, musculoskeletal, and psychiatric disorders, counted only if the corresponding ICD-10 code was present in the past 3 years before the index date). Although nitrate use at baseline was obtained from SwedeHF, nitrate use during follow-up was obtained from the Dispensed Drug Registry defined as dispension of isosorbide dinitrate (ATC code C01DA08) or isosorbide mononitrate (ATC code C01DA14). Finally, Statistics Sweden (www.scb. se) maintains demographic and socioeconomic data on all Swedish citizens and provided additional baseline data, including level of education and income.
Patients
Patients were included if their index date was between July 1, 2005 (start of the Dispensed Drug Registry), and December 31, 2012 (last follow-up for data linked to the Patient Registry for this study). The index date was defined as the date of an outpatient visit or discharge from hospital. LVEF is reported in SwedeHF as <30%, 30% to 39%, 40% to 49%, and ≥50%. For this study, HFpEF was defined as a LVEF of ≥40%. Although LVEF 40% to 49% is not considered normal, previous randomized clinical trials involving HF with reduced ejection fraction included patients with LVEF <35% 12 to 40%. 13 Furthermore, we performed a separate analysis for patients with LVEF ≥50% and a prespecified subgroup analysis by LVEF 40% to 49% versus ≥50%. Patients with missing data on LVEF (n=8876) and nitrate use (n=581) and those who died during the index hospitalization (n=1857) were excluded.
Outcomes
The primary outcome was time to all-cause mortality, and the secondary outcome was the composite of time to all-cause mortality or first HF hospitalization, for which an ICD-10 code for HF was in the first position.
Ethics
Establishment of the SwedeHF Registry and this analysis with linking of the above registries were approved by a multisite ethics committee. Individual patient consent was not required, but patients were informed of entry into national registries and allowed to opt out.
Statistical Analysis
Baseline clinical characteristics, medication use, and socioeconomic data were presented as mean (SD) or median (interquartile range [Q1-Q3]) and n (%) and compared with unpaired t tests and χ 2 tests.
A propensity score for treatment with nitrates at baseline (index date) was estimated for each patient with logistic regression using 52 relevant clinical and socioeconomic variables (Tables 1 and 2) as independent variables and nitrate use as the dependent variable. The propensity score is the propensity from 0 to 1 of receiving a treatment given a set of known patient characteristics and is used to attempt to adjust for potential selection bias, confounding, and differences between groups in observational studies.
14 Continuous variables were modeled using restricted cubic splines with 3 degrees of freedom. Missing data were accounted for by deriving separate logistic regressions for each missing variable pattern using available observations. This resulted in 1205 logistic regression models. Each individual received the propensity score from the model that incorporated all nonmissing variables for that individual. An age-matched and propensity score-matched cohort was constructed, using nearest-neighbor matching without replacement, 15 where the age differed by 5 or less years, and the propensity score differed by 0.01 or less. Matching was performed in a prespecified 2:1 ratio, where 2 untreated patients were matched with 1 treated patient. The success of matching was assessed using absolute standardized differences, with standardized differences of <10% considered clinically irrelevant. 16 Crude outcomes in the overall cohort were presented with Kaplan-Meier curves and compared using univariable Cox regression. Adjustment for potential confounders was made by comparing the outcomes in the matched cohort in a similar manner, where the dependence between matched pairs was modeled using a frailty term. We tested the proportional hazards assumption using scaled Schoenfeld residuals and assessed for potential outliers using the standardized difference of the beta (dfbetas) from the models, and the model assumptions were found to be acceptable. Interactions between nitrate use and prespecified clinically important variables were estimated by Cox regression and displayed in a forest plot with hazard ratios (HR) for subgroups for all-cause mortality for the matched population. Incidence rate of events per 1000 patient-years were calculated and presented with Poisson confidence intervals (CI) and tested for differences between groups with the Poisson test.
The main analysis was done as an intention-to-treat analysis. Prespecified consistency analyses were performed as (1) per-protocol analysis, where continued nitrate use was tracked prospectively in the Dispensed Drug Registry, and patients were censored at crossover and (2) because propensity score matching excludes patients thus limiting generalizability, also in the overall cohort, where adjustment was performed not by matching but by adjustment for propensity score as a continuous covariate. Prescriptions in Sweden are provided for 3-month intervals. To allow for patients having remaining pills from previous prescriptions, we defined crossover as de novo nitrate dispension for untreated patients and failure to refill nitrates within 6 months from baseline or last prescription for treated patients, in which case the censor date was set to 3 months from baseline or last prescription.
Statistical analyses were performed using R version 3.1.3. The level of significance was set at 5%, and all P values and CIs were 2 sided.
Results
A total of 19 047 patients with HFpEF were included in the overall cohort (Figure 1 ), of whom 3227 patients (17%) received nitrates at baseline. The age-matched and propensity score-matched cohort had 2235 treated and 4470 untreated patients. In the overall population (Table II in the Data Supplement), mean (SD) age was 76 (12) years, and 46% were women. Patients receiving nitrates were older, more commonly women, with more comorbidities, greater pulse pressure, longer duration of HF and more severe HF as reflected by inpatient status, NT-proBNP (N-terminal probrain natriuretic peptide), New York Heart Association class, hemoglobin, renal function, and diuretic use. As expected, treated patients had more coronary artery disease, angina, and use of (8) years, and 48% were women. Differences in propensity score were small between the treatment groups, and the standardized differences were ≤10% for most variables, with the exception of body mass index, NT-proBNP levels, and previous treatment with percutaneous coronary intervention and coronary artery bypass grafting (Tables 1 and 2 ).
Outcomes
In the overall cohort, the 1-year survival in treated compared with untreated patients was 79% (95% CI, 78%-80%) versus 84% (95% CI, 83%-84%) respectively. At 5 years, survival was 37% (95% CI, 35%-39%) versus 52% (95% CI, 51%-53%), respectively ( Figure 2 ). In the matched cohort, the 1-year survival in treated compared with untreated patients was 80% (95% CI, 78%-82%) versus 79% (95% CI, 78%-81%), respectively. At 5 years, survival was 39% (95% CI, 37%-42%) versus 42% (95% CI, 40%-44%), respectively ( Figure 2 ). The HR in the overall cohort (unadjusted) was 1.48 (95% CI, 1.40-1.56; P<0.001) and in the matched cohort was 1.06 (95% CI, 0.98-1.15; P=0.12; Table 3 ).
In the overall population, the 1-and 5-year event-free (mortality or first HF hospitalization) survival in treated versus untreated patients were 60% (95% CI, 58%-62%) and 24% (95% CI, 22%-26%) versus 71% (95% CI, 70%-71%) and 39% (95% CI, 38%-40%), respectively, and unadjusted HR was 1.51 (95% CI, 1.44-1.59; P<0.001). In the matched cohort, corresponding rates were 62% (95% CI, 60%-64%) and 26% (95% CI, 24%-29%) versus 65% (95% CI, 63%-66%) and 29% (95% CI, 27%-31%) respectively, and matched HR was 1.11 (95% CI, 1.04-1.18; P=0.003; Table 3 ).
Interaction and Subgroup Analyses
The association between use of nitrates and all-cause mortality for prespecified, clinically relevant subgroups, in the matched cohort and after adjustment for the interaction between nitrate use and the respective subgroup variables is depicted in a Forest plot (Figure 3 ). There were no statistically significant interactions.
Consistency Analyses
In the overall cohort, the HR after adjustment for propensity score was comparable to that of the matched cohort at 1.06 (95% CI, 0.99-1.13; P=0.11). In the per-protocol analysis, censoring because of crossover occurred in 1386 patients (43%) in the nitrates group at a median (Q1-Q3) of 244 days (96-557 days) and in 1462 patients (9%) in the non-nitrates 
Numbers are n (%) for categorical variables and mean±SD for continuous variables (except NT-proBNP [N-terminal probrain natriuretic peptide], which is median [interquartile range]). P is for differences between the groups by t test for continuous variables and χ
2 test for categorical variables. Blood pressures are given in mm Hg. Mean arterial pressure derived as systolic blood pressure×1/3+diastolic blood pressure×2/3. HF indicates heart failure; LVEF, left ventricular ejection fraction; and NYHA, New York Heart Association.
*Number of variables (52) included in derivation of the propensity score. †The difference between the means for the 2 groups divided by the mutual SD. ‡Derived from the unique personal identification number. group at a median (Q1-Q3) 189 days (57-572 days). Findings in the per-protocol analysis mirrored that of the main intention-to-treat analysis, both in the overall and matched HFpEF cohorts (Table 3) .
Analysis of Patients With LVEF ≥50%
In the overall cohort of 9702 HFpEF patients defined as LVEF ≥50% (baseline data presented in Table III in the Data Supplement), the results were similar ( 
29).
Results were also consistent with adjustment rather than matching for propensity score and in per-protocol analyses.
Discussion
In this large generalizable HFpEF population, nitrate use was not associated with reduced all-cause mortality and seemed associated with increased combined all-cause mortality or first HF hospitalization.
Nitrates are commonly used in HFpEF, with the 17% use in this study consistent with the 15% to 50% reported in the literature.
17- 20 The rationale for benefit in HFpEF lies in the notion of HFpEF as a state of inflammatory endothelial activation with reduced NO bioavailability in cardiomyocytes. 21 Administration of exogenous NO donors such as organic nitrates may improve endothelial function 22 and enhance NO-cGMP signaling, leading to enhanced lusitropy, improved LV compliance, and antihypertrophic and antifibrotic effects. Furthermore, nitrates cause venodilation, increasing peripheral venous capacitance and reducing preload, thus helping to reduce pulmonary congestion in HFpEF (as in HF with reduced ejection fraction). At higher concentrations, nitrates cause arterial vasodilatation in several circulatory beds, which offers potential benefit in HFpEF-coronary vasodilatation improves subendocardial perfusion, whereas vasodilatation in the pulmonary and systemic resistance vessels improves pulmonary hypertension and LV afterload, respectively.
Our findings are contrary to these theoretical benefits of organic nitrates, with neutral findings consistent with results of the NEAT-HFpEF trial. There are several possible explanations: patients receiving nitrates were rather ill, with predominant enrollment as inpatients (71%), a long duration of HF, a significant proportion on chronic diuretic use (87%), a high median NT-proBNP level of 2510 pg/mL, and a high event rate. Even after propensity score matching, the median NT-proBNP level was still higher in the treated group. Furthermore, even if there were no differences between the groups, the severity and progression of disease (regardless of nitrate use) and high event rate consistent with the unselective nature of this nationwide registry may have been beyond the modifiable stage. Indeed, in I-PRESERVE study (Irbesartan in Heart Failure with Preserved Ejection Fraction), patients with NT-proBNP levels below the median of 339 pg/mL may have responded to irbesartan, whereas those with higher levels did not, 23 suggesting a threshold beyond which HFpEF may not be modifiable.
The association between nitrate use and increased risk of the composite outcome was largely driven by HF hospitalizations. HF hospitalizations were not adjudicated, and the admissions may be related to complications of therapy or worsening of comorbidities, rather than worsening of HF itself. The long-term benefits of organic nitrates may be limited by tolerance (consequent to reactive oxygen species production, desensitization of sGC to NO, increased phosphodiesterase activity, increased endothelin expression, and enhanced sensitivity to vasoconstrictors) and pseudotolerance (with reflex activation of neurohormonal systems). 3, 4, 24, 25 Pseudotolerance not only effectively reverses the initial hemodynamic benefits of nitrate therapy but also may be deleterious in the HFpEF population vulnerable to changes in LV preload and afterload. HFpEF patients are exquisitely sensitive to volume changes, given the steep slope of the end-systolic pressure-volume relationship characteristic of this disease. 5, 6 This is compounded by attenuated baroreceptor reflexes among our elderly patients, rendering them susceptible to complications from nitrate therapy including symptomatic hypotension. The crossover rate of 43% in the nitrates group, while may be partly related to the lack of efficacy of nitrates, does support the notion that nitrates may have been poorly tolerated in our study population. This is consistent with the NEAT-HFpEF trial, where it was postulated that adverse side effects of high-dose nitrates (eg, headaches) may have limited activity levels of patients.
The majority of our patients were on β-blockers and renin-angiotensin system antagonists. Although their long-term efficacy in HFpEF has not been demonstrated conclusively in randomized controlled trials, both classes of drugs have been shown to improve endothelial function, [26] [27] [28] and the addition of nitrates on top of these may not further improve endothelial function. The setting of HF care may affect the propensity to use nitrates (and other interventions). In view of this, the propensity score derivation and interaction analyses included both location (inpatient versus outpatient physician consultation versus outpatient HF nurse consultation) and specialty (cardiology versus internal medicine/geriatrics). The main indication for nitrate therapy seemed to be coronary artery disease with potentially residual angina in our cohort. However, we are unable to discount physicians' subjective preferences and arbitrary impressions of symptoms such as atypical chest pain, anxiety, or HF symptoms such as dyspnea. This limits our ability to adjust for all confounders that may have dictated the decision for nitrate therapy. Treated patients received less specialized follow-up care even though they were sicker. This suggests that there was less motivation for further evaluation and treatment, a phenomenon consistent with the characteristics of the group (older age, women, living alone, and lower socioeconomic status). Although adjusted for, these demographic and socioeconomic factors are associated with other processes that predispose to worse outcomes, including frailty, behavioral patterns, neuropsychiatric stress, pre-existing deprivation, and comorbidity. Finally, HFpEF is a heterogeneous condition whose pathophysiology is not completely understood. There exists a complex interplay of endothelial dysfunction, autonomic abnormalities, chronotropic incompetence, and vascular stiffening, which lead to impairments in LV systolic and diastolic functions and limitations in cardiac output reserve and raised LV filling pressures. 29 The sole targeting of endothelial dysfunction by organic nitrates, with little effect on autonomic imbalance, chronotropic incompetence, and vascular stiffening, may not be sufficient to impact outcomes.
Strengths of this study include the large patient numbers, long duration of follow-up, and comprehensive baseline data that allowed for the generation of propensity scores and matching of cohorts, as well as broad coverage and thus external validity and generalizability of the findings. However, inaccuracies in registry data and residual confounding cannot be excluded in this observational study, which may limit the internal validity and reliability of the findings. Measurements of endothelial function or oxidative stress would have been of great interest but were not available in this study. Finally, although findings from this population-wide Swedish registry are generalizable to similar regions and ethnic groups, they may not be generalizable to other populations with different healthcare systems and ethnic makeup.
Despite our neutral findings, there may still be reason to explore nitrates in HFpEF. Nitrates in combination with hydralazine is currently being investigated in a phase II study (Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction, ClinicalTrials. gov identifier: NCT01516346). Also, inorganic nitrate and nitrite have shown promising results in the acute setting 30, 31 and may deserve further evaluation as a long-term therapy.
Conclusions
These real-world data from a large unselected HFpEF population suggested that nitrate use was not associated with mortality or morbidity benefit. 
Sources of Funding
This work was supported in part by The Swedish Research Council, The Swedish Heart and Lung Foundation, and The Stockholm County
Council in the form of grants to Dr Lund's institution. No funding organization had any role in the collection, analysis, or interpretation of data or approval/disapproval for publication. Hazard ratio and 95% confidence intervals (CI) for the primary outcome, all-cause mortality for treatment vs nontreatment with nitrates, in prespecified subgroups in the matched heart failure with preserved ejection fraction cohort, with P values for the interaction between nitrate use and the indicated characteristic. Continuous variables were categorized at clinically relevant cutoffs. CABG indicates coronary artery bypass graft; FU, follow up; HF, heart failure; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and RAS, renin-angiotensin system.
